Best in Biotech 5 Mar 2025 Seven biotech companies keeping Taiwan dynamic in 2025 …cytotoxic agent specifically to TROP2-expressing cancer cells, to minimize damage to normal tissues. Preclinical studies have demonstrated promising anti-tumor activity, leading to the advancement of OBI-992 into clinical development. In… March 5, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Startup Scout 6 Sep 2023 Meet the startup developing novel cancer therapies from snake venom crotoxin …that has an inbuilt targeting mechanism and selectivity for tumor cells. The therapy contains two subunits: A and B. “Once injected into the body via infusion pump, the A subunit… September 6, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2017 Picking the Perfect Time to Strike: How to Stop HIV in its Tracks …phagocytic cells to remove pathogens, could be a candidate to quickly take care of the infection. Complement coats the virus, making it easier for the immune system to detect and… November 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2018 A New Liquid Biopsy Can Improve Ovarian Cancer Diagnosis …whether a tumor is benign or malignant. “There are several major advantages to the circulating tumor cell technology. The first is it’s epitope or label-independent, so it doesn’t require the… March 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML …immuno-oncology candidate targeting the TRAIL-receptor. Apart from that, CAR-T pioneers such as Cellectis and Celyad or Juno are racing to treat leukemia including AML or ALL using their engineered killer… May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer …cells. In the lab, Genenta makes the stem cells mature into immune cells called tumor-infiltrating monocytes, and the company implants them into the patient’s tumor where they can recruit the… September 11, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …cells to treat cancer. The two companies will assess the combination therapies’ performances in preclinical studies next year. The FLEX-NK antibodies are based on a tetravalent, multifunctional format with flexible… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 …of CAR-T cell therapy and T-cell receptor technologies. Both approaches have shown great promise for cancer treatment, with the two first CAR-T therapies launched into the market in 2017. To… February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents …Celyad’s allogeneic CAR-T therapy. By using T cells derived from a healthy donor, allogeneic CAR-T therapy is thought to be more cost- and time-effective, allowing for off-the-shelf available T cells… May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer …for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. In particular, the collaboration… January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Debunking the Immuno-Oncology Hype: is it as good as it sounds? …are now advancing their programs in CAR-T, the breakthrough therapy that everyone’s after. In this treatment, the patient’s T-cells are engineered in vitro, rewired to attack a specific tumor antigen… September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Turning the tide: recent advancements in childhood cancer research …Last year, BrainChild took its CAR-T candidate to the clinic to evaluate four different targets. It plans to create a CAR-T cell therapy platform that can address multiple targets, include… February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email